140 related articles for article (PubMed ID: 2257052)
1. Characterization of immunostimulating complexes (ISCOMS) of HIV-1.
Höglund S; Akerblom L; Ozel M; Villacres M; Eriksson M; Gelderblom HR; Arthur L; Morein B
Viral Immunol; 1990; 3(3):195-206. PubMed ID: 2257052
[TBL] [Abstract][Full Text] [Related]
2. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
3. Specific western blot bands are associated with initial CD4+ lymphocyte counts in human immunodeficiency virus seroconverters. The Navy HIV Working Group.
Garland FC; Garland CF; Gorham ED; Brodine SK; Weiss PJ
Ann Epidemiol; 1994 Jan; 4(1):27-31. PubMed ID: 7911377
[TBL] [Abstract][Full Text] [Related]
4. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
5. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
[TBL] [Abstract][Full Text] [Related]
6. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
Akerblom L; Nara P; Dunlop N; Morein B
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 neutralizing antibodies in urine from seropositive individuals.
Cao YZ; Friedman-Kien AE; Mirabile M; Li XL; Alam M; Dieterich D; Ho DD
J Acquir Immune Defic Syndr (1988); 1990; 3(3):195-9. PubMed ID: 1968094
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of human immunodeficiency virus type 1 antibody reactivity by western immunoblots: evaluation of relative antibody levels in seropositive individuals and mothers.
Geffin RB; Lai SH; Hutto C; Scott GB; Scott WA; Master M; Parks WP
J Infect Dis; 1992 Jan; 165(1):111-8. PubMed ID: 1727880
[TBL] [Abstract][Full Text] [Related]
9. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of antibodies against HIV-1 proteins in seropositive drug addicts tested by the western blotting method].
Swiderska H; Kalinowska B
Przegl Epidemiol; 1992; 46(1-2):19-25. PubMed ID: 1475386
[TBL] [Abstract][Full Text] [Related]
11. Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1.
Robert V; Resnicoff M; Chermann JC; Devaux C
Mol Cell Biochem; 1991 Apr; 102(2):115-23. PubMed ID: 1715507
[TBL] [Abstract][Full Text] [Related]
12. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.
Takahashi H; Takeshita T; Morein B; Putney S; Germain RN; Berzofsky JA
Nature; 1990 Apr; 344(6269):873-5. PubMed ID: 2184369
[TBL] [Abstract][Full Text] [Related]
13. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles.
Haffar OK; Smithgall MD; Moran PA; Travis BM; Zarling JM; Hu SL
Virology; 1991 Aug; 183(2):487-95. PubMed ID: 1906660
[TBL] [Abstract][Full Text] [Related]
14. Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies.
Nair BC; Ford G; Kalyanaraman VS; Zafari M; Fang C; Sarngadharan MG
J Clin Microbiol; 1994 Jun; 32(6):1449-56. PubMed ID: 8077388
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
Becker Y
Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
[TBL] [Abstract][Full Text] [Related]
17. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
Neurath AR; Strick N; Li YY; Jiang S
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
[TBL] [Abstract][Full Text] [Related]
18. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).
Pyle SW; Morein B; Bess JW; Akerblom L; Nara PL; Nigida SM; Lerche NW; Robey WG; Fischinger PJ; Arthur LO
Vaccine; 1989 Oct; 7(5):465-73. PubMed ID: 2554608
[TBL] [Abstract][Full Text] [Related]
19. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
Thomas HI; Wilson S; O'Toole CM; Lister CM; Saeed AM; Watkins RP; Morgan-Capner P
Clin Exp Immunol; 1996 Feb; 103(2):185-91. PubMed ID: 8565298
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
